**Eli Lilly Seeks Approval for Experimental COVID-19 Antibody Drug**

**礼来制药公司申请批准新冠肺炎试验性抗体药物**

Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.

周三礼来制药公司表示，他们已申请美国官方批准在紧急情况下允许使用一种针对新冠肺炎的实验性抗体治疗药物。

Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.

礼来称一项研究的早期结果显示这种药物治疗减少了轻度或中度新冠肺炎患者的急诊就诊量。它还表示这种疗法还减少了新冠肺炎疾病的症状，减少了病毒的数量，减少了此类病人的住院时间。

The company announced the study’s partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists.

该公司在与投资者和公众的一次会晤前公布了研究的部分结果。这些研究结果尚未发表或由独立科学家进行检验。

The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals.

这种抗体治疗的效果似乎与上周五特朗普总统的治疗方法相似。特朗普总统接受的治疗由再生元制药公司开发。

Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.

这两种疗法都是将人类抗体与引发新冠肺炎的冠状病毒连接起来并限制其传播能力。抗体通常是通过静脉注射一次性治疗。

Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes.”

丹尼尔·斯科夫朗斯基是一位博士也是礼来制药公司的首席科学家。他在一份声明中称，“我们相信迄今为止的数据提供了足够的证据，证明单一疗法和联合疗法可能对治疗病情严重的高风险患者有效。”

The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.

单一疗法涉及一种叫做LY-CoV555的抗体。联合疗法将这种抗体与一种名为LY-CoV016的抗体结合起来。

The medical news website StatNews reported that “Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust.”

医学新闻网站StatNews报道称，“礼来此前曾发布过一种被专家评定为很有前景的类似的抗体治疗结果。但是从目前有限的数据来看，这种由两种抗体组合而成的新疗法的实验结果似乎更加可靠。”

The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.

礼来制药公司要求美国食品和药物管理局(FDA)允许在紧急情况下使用其单一抗体治疗。该公司预计将在11月寻求政府批准联合抗体治疗。

At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president’s personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.

目前，美国食品和药物管理局只批准了瑞德西韦用于新冠肺炎患者的紧急治疗。总统的私人医生证实，特朗普也已开始使用瑞德西韦进行为期5天的治疗。

Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year’s end.

礼来公司表示，他们已经开始生产药物LY-CoV555。该公司预计10月份将有10万剂疫苗准备就绪，到今年年底将达到100万剂。它希望在年底前能制成5万剂联合抗体药物。

The drug maker added that it is also “working with regulators around the world to make these treatments available."

这家药品生产商还补充道，它还“与世界各地的监管机构合作促使这种疗法投入使用。”

I'm Jonathan Evans.

乔纳森·埃文斯报道。

**Eli Lilly Seeks Approval for Experimental COVID-19 Antibody Drug**

Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.

Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.

The company announced the study’s partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists.

The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals.

Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.

Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes.”

The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.

The medical news website StatNews reported that “Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust.”

The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.

At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president’s personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.

Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year’s end.

The drug maker added that it is also “working with regulators around the world to make these treatments available."

I'm Jonathan Evans.